Sanjukta Chakraborty

Dr. Sanjukta Chakraborty

Texas A&M University, College Station, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
PBPriyanka Banerjee
Priyanka Banerjee
NGNiyanshi Gaddam
Niyanshi Gaddam
VCVanessa Chandler
Vanessa Chandler
Sanjukta ChakrabortySanjukta Chakraborty
Sanjukta Chakraborty

27 June 2020 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
SRSukanya Roy
Sukanya Roy
SKSubhashree Kumaravel
Subhashree Kumaravel
ASAnkith Sharma
Ankith Sharma
CDCamille L Duran
Camille L Duran
KBKayla J Bayless
Kayla J Bayless
Sanjukta ChakrabortySanjukta Chakraborty
Sanjukta Chakraborty
Hypoxia or low oxygen concentration in tumor microenvironment has widespread effects ranging from altered angiogenesis and lymphangiogenesis, tumor metabolism, growth, and therapeutic resistance in different cancer types. A large number of these effects are mediated by the transcription factor hypoxia inducible factor 1⍺ (HIF-1⍺) which is activated by hypoxia. HIF1⍺ induces glycolytic genes and reduces mitochondrial respiration rate in hypoxic tumoral regions through modulation of various cells in tumor microenvironment like cancer-associated fibroblasts. Immune evasion driven by HIF-1⍺ further contributes to enhanced survival of cancer cells. By altering drug target expression, metabolic regulation, and oxygen consumption, hypoxia leads to enhanced growth and survival of cancer cells. Tumor cells in hypoxic conditions thus attain aggressive phenotypes and become resistant to chemo- and radio- therapies resulting in higher mortality. While a number of new therapeutic strategies have succeeded in targeting hypoxia, a significant improvement of these needs a more detailed understanding of the various effects and molecular mechanisms regulated by hypoxia and its effects on modulation of the tumor vasculature. This review focuses on the chief hypoxia-driven molecular mechanisms and their impact on therapeutic resistance in tumors that drive an aggressive phenotype.Impact statement: Hypoxia contributes to tumor aggressiveness and promotes growth of many solid tumors that are often resistant to conventional therapies. In order to achieve successful therapeutic strategies targeting different cancer types, it is necessary to understand the molecular mechanisms and signaling pathways that are induced by hypoxia. Aberrant tumor vasculature and alterations in cellular metabolism and drug resistance due to hypoxia further confound this problem. This review focuses on the implications of hypoxia in an inflammatory TME and its impact on the signaling and metabolic pathways regulating growth and progression of cancer, along with changes in lymphangiogenic and angiogenic mechanisms. Finally, the overarching role of hypoxia in mediating therapeutic resistance in cancers is discussed.

1 September 2007 in Genomics
Verified
Journal Article
Closed access
Sanjukta ChakrabortySanjukta Chakraborty
Sanjukta Chakraborty
SKSonal Khare
Sonal Khare
SDSyril Kumar Dorairaj
Syril Kumar Dorairaj
VPVenkatesh C. Prabhakaran
Venkatesh C. Prabhakaran
DPD. Ravi Prakash
D. Ravi Prakash
AKArun Kumar
Arun Kumar

12 December 2012 in Microcirculation
Verified
Journal Article
Closed access
PDF file
Sanjukta ChakrabortySanjukta Chakraborty
Sanjukta Chakraborty
MGManokaran Gurusamy
Manokaran Gurusamy
DZDavid C. Zawieja
David C. Zawieja
MMMariappan Muthuchamy
Mariappan Muthuchamy

6 June 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Sanjukta ChakrabortySanjukta Chakraborty
Sanjukta Chakraborty
SMSm Azeem Mohiyuddin
Sm Azeem Mohiyuddin
KGKs Gopinath
Ks Gopinath
AKArun Kumar
Arun Kumar
Background: Despite extensive research, the five-year survival rate of oral squamous cell carcinoma (OSCC) patients has not improved. Effective treatment of OSCC requires the identification of molecular targets and signaling pathways to design appropriate therapeutic strategies. Several genes from the mTOR signaling pathway are known to be dysregulated in a wide spectrum of cancers. However, not much is known about the involvement of this pathway in tumorigenesis of OSCC. We therefore investigated the role of the tumor suppressor genes, TSC1 and TSC2, and other members of this pathway in tumorigenesis of OSCC. Methods: Expression of genes at the RNA and protein levels was examined by semi-quantitative RT-PCR and western blot analyses, respectively. Loss of heterozygosity was studied using matched blood and tumor DNA samples and microsatellite markers from the TSC1, TSC2 and PTEN candidate regions. The effect of promoter methylation on TSC gene expression was studied by treating cells with methyltransferase inhibitor 5-azacytidine. Methylation status of the TSC2 promoter in tissue samples was examined by combined bisulfite restriction analysis (COBRA). Results: The semi-quantitative RT-PCR analysis showed downregulation of TSC1, TSC2, EIF4EBP1 and PTEN, and upregulation of PIK3C2A, AKT1, PDPK1, RHEB, FRAP1, RPS6KB1, EIF4E and RPS6 in tumors. A similar observation was made for AKT1 and RPS6KB1 expression in tumors at the protein level. Investigation of the mechanism of downregulation of TSC genes identified LOH in 36.96% and 39.13% of the tumors at the TSC1 and TSC2 loci, respectively. No mutation was found in TSC genes. A low LOH rate of 13% was observed at the PTEN locus. Treatment of an OSCC cell line with the methyltransferase inhibitor 5-azacytidine showed a significant increase in the expression of TSC genes, suggesting methylation of their promoters. However, the 5-azacytidine treatment of non-OSCC HeLa cells showed a significant increase in the expression of the TSC2 gene only. In order to confirm the results in patient tumor samples, the methylation status of the TSC2 gene promoter was examined by COBRA. The results suggested promoter hypermethylation as an important mechanism for its downregulation. No correlation was found between the presence or absence of LOH at the TSC1 and TSC2 loci in 50 primary tumors to their clinicopathological variables such as age, sex, T classification, stage, grade, histology, tobacco habits and lymph node metastasis. Conclusion: Our study suggests the involvement of TSC genes and other members of the mTOR signaling pathway in the pathogenesis of OSCC. LOH and promoter methylation are two important mechanisms for downregulation of TSC genes. We suggest that known inhibitors of this pathway could be evaluated for the treatment of OSCC.

1 February 2015 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
Sanjukta ChakrabortySanjukta Chakraborty
Sanjukta Chakraborty
MDMichael Davis
Michael Davis
MMMariappan Muthuchamy
Mariappan Muthuchamy